Atea Pharmaceuticals Reports Positive Phase 3 Trial Results for Hepatitis C Treatment
Atea Pharmaceuticals Inc. announced positive results from its pivotal North American Phase 3 clinical trial, C-BEYOND, evaluating an oral antiviral therapy for chronic hepatitis C virus (HCV) infection. The study met its primary endpoint and showed that the once-daily fixed-dose combination of bemnifosbuvir and ruzasvir was statistically non-inferior to Gilead Sciences Inc.'s Epclusa in a modified intent-to-treat population. The trial involved 905 patients, with cure rates comparable across treatment groups. In the overall analysis, including both cirrhotic and non-cirrhotic patients, Atea's drug achieved a sustained virologic response rate of 93.9%, compared to 94.8% for Epclusa. The therapy also demonstrated strong tolerability with no serious adverse events or treatment discontinuations due to side effects. Atea is currently conducting the global C-FORWARD trial, which has enrolled over 880 participants across 17 countries and aims to evaluate additional viral genotypes. Topline data from this study are expected in early 2027.